Literature DB >> 18334136

Treatment of cerebellar masses.

Mahmut Edip Gurol1, Erik K St Louis.   

Abstract

Cerebellar masses are a heterogenous group of conditions that can cause compression of the aqueduct or fourth ventricle, resulting in obstructive hydrocephalus, brainstem compression, and upward/downward herniation as a direct result of mass effect. Untreated lesions can be fatal in a few hours, but prompt and appropriate treatment of the mass effect can produce very good outcomes. These patients should be closely followed in a critical care setting that has rapid access to neurosurgical expertise. Medical measures to decrease brain edema should be taken, including elevation of the head of the bed and avoidance of hypo-osmolar solutions, hypercarbia, or hyperthermia. Osmotic diuretics should be initiated promptly in patients with clinical worsening and radiographic evidence of edema resulting in mass effect. However, medical measures should not delay surgical intervention, which should proceed as rapidly as possible when indicated. Cerebellar hemorrhages more than 3 cm in diameter and cerebellar hemispheric strokes involving more than one third of the hemisphere should be considered for early suboccipital craniotomy with decompression. Regardless of lesion size, neurologic deterioration and radiologic signs of obstructive hydrocephalus should call for emergency decompressive surgery with resection of hematoma or necrotic brain tissue. Ventriculostomy should be considered as a bridge to surgical decompression, given the theoretical concern of upward herniation mediated by supratentorial drainage in the face of an underlying posterior fossa mass lesion. Steroids are not indicated for cerebrovascular disease but should be used to treat vasogenic edema induced by tumor. Anticoagulation is reserved for cerebellar venous and dural sinus thrombosis. Specific treatments targeting the underlying pathology should be used aggressively: thrombolysis and endovascular interventions for eligible stroke patients, antibiotic therapy for abscesses, and radiotherapy, chemotherapy, or both for tumors.

Entities:  

Year:  2008        PMID: 18334136     DOI: 10.1007/s11940-008-0015-z

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  63 in total

1.  Cerebral Edema: Hypertonic Saline Solutions.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-07       Impact factor: 3.598

Review 2.  Every breath you take: hyperventilation and intracranial pressure.

Authors:  Claudia Robertson
Journal:  Cleve Clin J Med       Date:  2004-01       Impact factor: 2.321

3.  EFNS guideline on the treatment of cerebral venous and sinus thrombosis.

Authors:  K Einhäupl; M-G Bousser; S F T M de Bruijn; J M Ferro; I Martinelli; F Masuhr; J Stam
Journal:  Eur J Neurol       Date:  2006-06       Impact factor: 6.089

4.  Management of spontaneous cerebellar hematomas: a prospective treatment protocol.

Authors:  R W Kirollos; A K Tyagi; S A Ross; P T van Hille; P V Marks
Journal:  Neurosurgery       Date:  2001-12       Impact factor: 4.654

5.  Surgical and medical management of patients with massive cerebellar infarctions: results of the German-Austrian Cerebellar Infarction Study.

Authors:  M Jauss; D Krieger; C Hornig; J Schramm; O Busse
Journal:  J Neurol       Date:  1999-04       Impact factor: 4.849

6.  Steroid therapy in acute cerebral infarction.

Authors:  J W Norris
Journal:  Arch Neurol       Date:  1976-01

7.  Cerebellar infarction: natural history, prognosis, and pathology.

Authors:  R A Macdonell; R M Kalnins; G A Donnan
Journal:  Stroke       Date:  1987 Sep-Oct       Impact factor: 7.914

8.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

9.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Authors:  Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

10.  Major clinical and physiological benefits of early high doses of mannitol for intraparenchymal temporal lobe hemorrhages with abnormal pupillary widening: a randomized trial.

Authors:  Julio Cruz; Giulio Minoja; Kazuo Okuchi
Journal:  Neurosurgery       Date:  2002-09       Impact factor: 4.654

View more
  2 in total

Review 1.  Management of intracerebral hemorrhage.

Authors:  Mahmut Edip Gurol; Steven M Greenberg
Journal:  Curr Atheroscler Rep       Date:  2008-08       Impact factor: 5.113

Review 2.  Medical and Nonstroke Neurologic Causes of Acute, Continuous Vestibular Symptoms.

Authors:  Jonathan A Edlow; David E Newman-Toker
Journal:  Neurol Clin       Date:  2015-08       Impact factor: 3.787

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.